Market Closed - London S.E. 11:35:22 2024-04-18 am EDT 5-day change 1st Jan Change
313 GBX -0.63% Intraday chart for MaxCyte, Inc. -5.15% -11.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
MaxCyte inks deal with Be Bio; Orcadian firms farmout AN
MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines CI
BTIG Adjusts Price Target on MaxCyte to $8 From $10, Maintains Buy Rating MT
MaxCyte loss widens in 2023 as core revenue declines 25% AN
North American Morning Briefing : Stock Futures Flat After S&P 500 Hit Record High DJ
MaxCyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : MaxCyte, Inc., 2023 Earnings Call, Mar 12, 2024
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (MXCT) MAXCYTE Reports Q4 Revenue $15.7M, vs. Street Est of $15.1M MT
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024 CI
EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit AN
MaxCyte Reaffirms Fiscal 2023 Revenue Guidance MT
MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024 CI
MaxCyte, Wugen Enter Platform License Deal MT
MaxCyte signs licencing deal with cell therapy company Wugen AN
MaxCyte, Inc. and Wugen, Inc. Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-The-Shelf Cell Therapies for Cancers CI
MaxCyte chief scientific officer leaves firm AN
MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer CI
Esken's Southend Airport faces further allegations AN
MaxCyte Inks Platform License Deal With Cancer Medicine Developer Imugene MT
MaxCyte, Inc. Signs Strategic Platform License with Imugene to Advance Their Cancer Immunotherapy Programs CI
MaxCyte's strategic platform licences redeem otherwise modest results AN
MaxCyte Preliminary Q4 Revenue Guidance Above Market Expectations; Shares Surge Premarket MT
MaxCyte Reports Preliminary Q4 Revenue; Shares Rise After Hours MT
MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Chart MaxCyte, Inc.
More charts
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.901 USD
Average target price
9.631 USD
Spread / Average Target
+146.87%
Consensus
  1. Stock Market
  2. Equities
  3. MXCT Stock
  4. News MaxCyte, Inc.
  5. MaxCyte Secures Strategic Platform License Deal; London Stocks Jump 7%